Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Broader pneumonia protection for babies? new vaccine trial shows promise

NCT ID NCT01692886

Vaccine Sponsor: Pfizer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial tested a 13-valent pneumococcal vaccine (13vPnC) against the older 7-valent version in over 1,600 healthy infants in China. The goal was to see if the newer vaccine triggers a stronger immune response and is just as safe. Infants received four doses starting at 3 months old, and researchers measured antibody levels and side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
13-valent pneumococcal conjugate vaccine (13vPnC)
What this could lead to
If successful, this vaccine could provide broader protection against pneumococcal infections in infants, reducing the risk of serious diseases like pneumonia and meningitis.
What could go wrong
This trial is completed, so results are available. However, the vaccine may not be as effective in real-world settings or may cause side effects like fever or injection-site reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

1,674 people

The number who actually took part.

Start date

Sep 2012

Finished

Apr 2014

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

42 to 77 days

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Aged 42 to 77 days (approximately 2 months) at the time of enrollment. 2. Healthy infant as determined by medical history, physical examination, and judgment of the investigator. Exclusion Criteria: 1. Previous vaccination with licensed or investigational pneumococcal vaccine. 2. A previous anaphylactic reaction to any vaccine or vaccine-related component. 3. Contraindication to vaccination with pneumococcal vaccines.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pneumococcal infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

pneumococcal infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pneumococcal infection

Contacts and locations

Locations

  • Jiangsu Province Guanyun County Center for Disease prevention and Control

    Guanyun County,, Jiangsu, 222200, China

  • Jiangsu Province Hongze County Center for Disease prevention and Control

    Huaian City, Jiangsu, 223100, China

  • Jiangsu Province Huaiyin District Center for Disease prevention and Control

    Huaian City,, Jiangsu, 223300, China

  • Jiangsu Province Lianshui County Center for Disease prevention and Control

    Lianshui County, Jiangsu, 223400, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.